What did @simidoctors actually say?
The creator opened with a joke, then walked it back immediately. They said "a lot of people are reporting" penis enlargement on GLP-1 medications, but their actual explanation was sensible: the effect is probably cosmetic, not anatomical. Fat loss around the pubic area, the fat pad that can partially obscure penile length, makes the penis appear larger. They were clear: "I don't think these GLP-1s are actually making the penis itself grow."
That's an important distinction. The framing leaned into the viral angle (and the 32K views suggest it worked), but the substantive claim was measured. The doctor was using a tabloid hook to deliver a reasonable anatomical explanation. Whether that tradeoff serves patients or just algorithms is a fair question.
Does the science back this up?
On the core mechanism, yes. The concept of a "buried penis" or apparent shortening due to suprapubic fat accumulation is well-documented in urological literature. As men gain weight, the fat pad anterior to the pubic symphysis can significantly reduce visible penile length without any change to actual stretched penile length.
Research on bariatric surgery patients has consistently shown that significant weight loss correlates with improved perceived and functional penile length. A study by Dallago et al. (2019, International Journal of Impotence Research) documented improvements in erectile function and self-reported penile dimensions following bariatric-related weight loss. The mechanism is purely geometric: less fat, more visible shaft.
There are no published peer-reviewed studies demonstrating that GLP-1 receptor agonists directly stimulate penile tissue growth. The claim that GLP-1s "make the penis itself grow" has no mechanistic basis in current pharmacology. GLP-1 receptors are expressed in various tissues, but there is no evidence they influence corporal smooth muscle proliferation or penile elongation.
What did they get wrong (or right)?
They got the mechanism right. Fat pad reduction explaining apparent penile enlargement is anatomically accurate and consistent with the bariatric surgery literature. Credit where it's due: the doctor resisted the temptation to just run with the viral claim.
Where this gets shakier is the framing: "a lot of people are reporting this, really." That's anecdotal signal, not clinical evidence. There is no published case series, no pharmacovigilance data from the FDA Adverse Event Reporting System (FAERS), and no study documenting GLP-1-associated penile enlargement as a discrete reported outcome. Treating social media comments as emerging pharmacological data is a methodological problem. Patient-reported outcomes matter, but they need context.
The joke about "injecting your penis" was clearly a joke, but on TikTok, context collapses fast. Someone will screenshot that sentence without the three seconds before it. That's not the creator's fault entirely, but it's a real risk of this format.
What should you actually know?
GLP-1 receptor agonists like semaglutide and tirzepatide produce meaningful weight loss, and that weight loss has documented effects on sexual health, body image, and physical function. A 2023 analysis published in Diabetes, Obesity and Metabolism (Lingvay et al.) noted improvements in patient-reported quality of life scores, including domains related to sexual function, in participants on semaglutide versus placebo.
The practical takeaway is this: if someone on a GLP-1 notices changes in their body that seem unexpected, fat redistribution and loss is almost always the explanation, not direct pharmacological action on that tissue. Losing 15-20% of body weight changes how your body looks and how clothing fits. That includes the groin area.
If you notice genuinely unusual physical changes while on any GLP-1 medication, the right move is to report them to your prescribing clinician. Not to comment sections, and not to self-experiment with anything injected elsewhere.